title: Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
abstract: Clinical differences between anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALK(-) ALCL) and peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), remain unclear. The aim of this study was to compare the clinical and prognostic features of these two lymphoma types. We retrospectively analyzed 167 patients with ALK(-) ALCL (n = 48) and PTCL-NOS (n = 119). Compared with ALK(-) ALCL patients, PTCL-NOS patients exhibited distinct differences in clinical features with a propensity for more advanced stages, frequent extranodal involvement, and a poor performance status, leading to a higher risk group according to the International Prognostic Index or Prognostic Index for PTCL-NOS. Patients with ALK(-) ALCL were associated with a higher complete response rate (47.9 vs. 31.0 %; P = 0.041) after initial chemotherapy than patients with PTCL-NOS. The prognosis was significantly different between two subtypes, with a 5-year overall survival (OS) rate of 57.9 % for ALK(-) ALCL and 23.9 % for PTCL-NOS (P = 0.002). The subgroup analysis showed significant differences in OS and progression-free survival between the two subtypes in early-stage diseases, but not in advanced-stage diseases. We conclude that patients with ALK(-) ALCL showed favorable clinical features, higher chemosensitivity, and a superior outcome than those with PTCL-NOS.
authors.affiliation: Departments of Radiation Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People's Republic of China.
authors.forename: Xiu-Wen
authors.initials: XW
authors.lastname: Deng
authors.affiliation: Departments of Radiation Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People's Republic of China.|Cancer Hospital, Tianjin Medical University, Tianjin, People's Republic of China.
authors.forename: Xi-Mei
authors.initials: XM
authors.lastname: Zhang
authors.affiliation: Departments of Radiation Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People's Republic of China.
authors.forename: Wei-Hu
authors.initials: WH
authors.lastname: Wang
authors.affiliation: Departments of Radiation Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People's Republic of China.
authors.forename: Shu-Lian
authors.initials: SL
authors.lastname: Wang
authors.affiliation: Departments of Radiation Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People's Republic of China.
authors.forename: Jing
authors.initials: J
authors.lastname: Jin
authors.affiliation: Departments of Radiation Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People's Republic of China.
authors.forename: Hui
authors.initials: H
authors.lastname: Fang
authors.affiliation: Departments of Radiation Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People's Republic of China.
authors.forename: Hua
authors.initials: H
authors.lastname: Ren
authors.affiliation: Departments of Radiation Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People's Republic of China.
authors.forename: Yue-Ping
authors.initials: YP
authors.lastname: Liu
authors.affiliation: Medical Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People's Republic of China.
authors.forename: Xiao-Hui
authors.initials: XH
authors.lastname: He
authors.affiliation: Medical Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People's Republic of China.
authors.forename: Mei
authors.initials: M
authors.lastname: Dong
authors.affiliation: Departments of Radiation Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People's Republic of China.
authors.forename: Yong-Wen
authors.initials: YW
authors.lastname: Song
authors.affiliation: Departments of Radiation Oncology, Cancer Hospital and Institute, Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences (CAMS), Beijing, 100021, People's Republic of China. yexiong12@163.com.
authors.forename: Ye-Xiong
authors.initials: YX
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy* / Q000201:enzymology / Q000532:radiotherapy; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000201:enzymology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D011379:Prognosis; D016016:Proportional Hazards Models; D011878:Radiotherapy / Q000379:methods; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism; D012074:Remission Induction; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases
keywords: ALK-negative anaplastic large-cell lymphoma; Chemotherapy; Peripheral T cell lymphoma, not otherwise specified; Prognosis; Radiotherapy